Affiliations: [a] Department of Pediatrics, Yangxin County Hospital of Traditional Chinese Medicine, Binzhou, Shandong, China
| [b] Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, China
Correspondence:
[*]
Corresponding author: Li Li, Clinical Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, China. E-mail: [email protected].
Abstract: The new heterocyclic compound 4-methyl-3-((4-(pyridin-3-yl) pyrimidin-2-yl) amino) benzoic acid (1) designed utilizing methyl 3-amino-4-methylbenzoate (2) as a starting material was successfully fabricated and eventually characterized utilizing single crystal X-ray crystallography, 1H NMR and IR. In biological study, to evaluate the protective effect of compound on acute tracheobronchitis ICR mice model, the ELISA assay was performed to determine the level of inflammatory mediators IL-6 and TNF-α in serum. Then, the western blot was performed to determine the activation of PKA-NF-κB pathway in tissues.
